Pharmacodynamic Modeling of Vincristine in Lymphoma Patients
![]() |
Seo, Jeong-Won
(New Drug Research Team, National Institute of Food and Drug Safety Evaluation (NIFDA))
Kim, Dong-Hyun (College of Pharmacy, Chungnam National University) Yun, Jin-Sang (Chungnam National University Hospital) Kim, Seon-Hwa (Division of Pharmacological Reserch, National institute of Food and Drug Evaluation, Korea Food & Drug Evaluation) Choi, Bo-Yoon (College of Pharmacy, Seoul National University) Oh, Jung-Mi (College of Pharmacy, Seoul National University) Kwon, Kwang-Il (College of Pharmacy, Chungnam National University) |
1 | Harris RA, Penington DG. The effects of low-dose vincristine on megakaryocyte colony-forming cells and megakaryocyte ploidy. Br J Haematol 1984; 57: 37-48. DOI |
2 | Rak K. Effect of vincristine on platelet production in mice. Br J Haematol 1972; 22: 617-24. DOI ScienceOn |
3 | Kelton JG, McDonald JW D, Barr RM, et al., The reversible binding of vinblastine to platelets: implications for therapy. Blood 1981; 57: 431-8. |
4 | http://www.druginfo.co.kr. |
5 | Donita L. Frazier and G. Sylvester Price. Use of body surface Area to Calculate Chemotherapeutic Drug Dose in Dogs : II. Limatations Imposed by Pharmacokinetic factors. 1998; 12: 272-278. DOI ScienceOn |
6 | John J. Reilly, Paul Workman. Normalisation of anticancer drug dosage using body weight and surface area : is it worthwhile? 1993; 32: 411-418. DOI ScienceOn |
7 | Gurney H .Dose calculation of anticancer drugs:a review of the current practice and introduction of an alternative. Journal of Clinical Oncology, vol 14. 1996: 2590-2611. DOI |
8 | Ratain MJ. Body surface area as a basis for dosing of anticancer agents:science, myth,or habit?. Journal of Clinical Oncology ,vol 16,no7, 1998: 2297-2298. DOI |
9 | Gurney H. How to calculate the dose of chemotherapy. Brithsh Journal of cancer, 2002: 1297-1302 |
10 | Bo Gao, Heinz-Jose Klumpen, Gurney H. Dose calculation of anticancer drugs. informa healthcare vol 4, 2008: 1307- 1319. |
11 | Lamya Alnaim, Therapeutic drug monitoring of cancer chemotherapy.Jounnal of Oncology Pharmacy Practice vol 14 no 4 2007: 207-221. |
12 | Sawyer M, Ratain Mark J. Body surface area as a determination of pharmacokinetics and drug dosing. Investigational new drugs 19 2001: 171-177. DOI ScienceOn |
13 | D.Pinkel. The use of body surface area as a criterion of Drug dosage in Cancer Chemotherapy. Cancer Res. 1958 Aug;18(7): 853-6. |
14 | Costa G, Hreshchyshyn, Holland J. Initial studies with vincristine. Cancer Chemother Rep 1962; 24: 39-43. |
15 | Johnson I, Armstrong J, Gorman M. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963; 23: 1390-427. |
16 | B-M Frost, G Lönnerholm, P Koopmans, et al., DRA Uges and SSN de Graaf. Vincristine in childhood leukemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 2003: 92: 551-557. DOI ScienceOn |
17 | 이성문, 함순식, 전인상. 급성 림프구성 백혈병의 항암 유 지요법 중 vincristine과 관련된 혈소판수의 변화, Korean Journal of Pediatrics Vol. 49. No.2.2006 :181-186. DOI |
18 | 강형진, 신희영, 안효섭. 소아 급성 림프모구 백혈병: 과거, 현재, 미래 Korean Journal of Pediatrics Vol. 50. No.7.2007 : 601-605. DOI ScienceOn |
19 | Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 1993; 17: 269-81. |
20 | Owellen RJ, Hartke CA, Dickerson RM, et al., Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res 1976; 36: 1499-502. |
21 | Rowinsky EK, Donehower RC. Antimicrotubule agents. In : Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy principles and practice. 2nd ed. Philadelphia : Lippincott-Raven Co, 1996: 26-96. |
22 | Giannakakou P, Sackett DL, Ward Y, et al., p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2000; 2:709-17. DOI ScienceOn |
23 | Allen JC .The effects of cancer theraphy on the nervous system.J Pediatr 1978; 93: 903-909. DOI |
24 | Legha SS. Vincristine neurotoxity.Pathophysiology and managemant. Med Toxicol 1986; 1: 421-427. DOI |
25 | Hussain M, Wozniak AJ, Edelstein MB. Neurotoxicity of antineoplatic agents. Crit Rev Oncol Hematol 1993; 14: 61- 75. DOI ScienceOn |
26 | Gidding CE, Kellie SJ, Kamps WA, et al., Vincristine revisited. Crit Rev Oncol Hematol 1999; 29: 267-287. DOI ScienceOn |
27 | Sawyer M, Ratain Mark J. Body surface area as a determination of pharmacokinetics and drug dosing. Investigational new drugs 19 2001: 171-177. DOI ScienceOn |
28 | Freireich EJ, Gehan EA, Rall DP, et al., Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966 May; 50(4): 219-44. |
![]() |